Navigation Links
OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R5
Date:1/10/2011

REDWOOD CITY, Calif., Jan. 10, 2011 /PRNewswire/ -- OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells, today announced that patient dosing has commenced in a Phase 1 clinical trial of OMP-59R5 in patients with advanced solid tumor cancers.  

OMP-59R5 is a monoclonal antibody that binds selected Notch receptors and is the first antibody to specifically block these targets to enter human studies.  The Phase 1 clinical trial of OMP-59R5 is a single-agent study designed to evaluate the safety of escalating doses of OMP-59R5 in patients who have received prior treatment with standard chemotherapeutics.  The study will also assess pharmacokinetics, biomarkers and initial indications of efficacy.  The Phase 1 trial is being conducted at leading U.S. cancer treatment centers.  Preclinical studies have demonstrated that OMP-59R5 decreases the frequency of tumor-initiating cells across a variety of tumor types.  

"The advancement of our second antibody into the clinic represents an important milestone for OncoMed, demonstrating our robust and productive drug discovery capabilities and steady execution on our objectives for our programs," said Paul Hastings, President and Chief Executive Officer of OncoMed Pharmaceuticals.  "In just a few short years, we have established a rich pipeline of first-in-class anti-cancer stem cell therapeutics with the potential to dramatically transform cancer treatment by directly targeting tumor-initiating cells."  

OMP-59R5 is part of OncoMed's collaboration with GlaxoSmithKline (GSK) and its advancement to the clinic triggers a milestone payment from GSK for the company.  In December 2007, OncoMed and GSK entered into a strategic alliance valued at up to $1.4 billion to develop cancer stem cell antibody therapeutics targeting the Notch signaling pathway.  OncoMed is currently conducting Phase 1 single agent and Ph
'/>"/>

SOURCE OncoMed Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
2. SynCo Expands Agreement with OncoMed Pharmaceuticals to Manufacture Cancer Stem Cell Antibodies
3. Bayer and OncoMed Pharmaceuticals Enter Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
4. OncoMed Pharmaceuticals Awarded Five Therapeutic Discovery Project Grants Totaling $1.2 Million
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... N.C. , Aug. 28, 2015  Delays ... research projects can slow down the decision-making process, ... is, therefore, absolutely critical for biopharmaceutical companies to ... research approval process for quicker and more meaningful ... by Best Practices, LLC, nearly three-quarters of benchmarked ...
(Date:8/28/2015)... -- Research and Markets ( ... "Investigation Report on China,s Pranoprofen Market, 2010-2019" ... discovered by Welfide (Mitsubishi Tanabe Pharma Corporation formerly ... inflammatory drug, pranoprofen was later developed into eye ... trade name of pranopulin for the treatment of ...
(Date:8/28/2015)... Research and Markets ( http://www.researchandmarkets.com/research/jq34zf/investigation ) ... on China,s Tobramycin Market, 2010-2019" report to their ... eye drop and ointment are the most common prescription ... caused by eye infection. Currently, dozens of enterprises in ... tobramycin, among which the Top 5 are s.a. Alcon- ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Pranoprofen Market, 2010-2019 2Investigation Report on China's Tobramycin Market, 2015-2019 2
... NEW YORK, Sept. 5, 2011 Reportlinker.com announces ... in its catalogue: U.S. Market ... http://www.reportlinker.com/p0610531/US-Market-for-Emergency-Room-Equipment-2011.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging In 2010, the ... at over $960 million. The U.S. market for ...
... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced ... Baird,s 2011 Health Care Conference Onyx ... September 7, 2011 at 11:30 a.m. Eastern Time (8:30 a.m. ... 2011 Subsequently, Onyx will present at the Stifel Nicolaus ...
Cached Medicine Technology:U.S. Market for Emergency Room Equipment 2011 2U.S. Market for Emergency Room Equipment 2011 3U.S. Market for Emergency Room Equipment 2011 4U.S. Market for Emergency Room Equipment 2011 5U.S. Market for Emergency Room Equipment 2011 6U.S. Market for Emergency Room Equipment 2011 7
(Date:8/31/2015)... ... August 31, 2015 , ... Now through October 31st, the ... be featured on a digital screen projected above New York’s Times Square, on ... promote earlier awareness of the symptoms of ovarian cancer, and earlier conversations with ...
(Date:8/31/2015)... ... ... All birth control methods work best if used correctly every time you have ... Moreover, no-scalpel vasectomy has many proven advantages with a lower complication rate over the ... are afraid of complications. , One Stop Medical Center reported a zero failure ...
(Date:8/31/2015)... ... ... TheHardwareCity.com is pleased to announce the availability of the technologically-advanced and easy ... are manufactured by Allied Tools. The set consists of a selection of basic tools ... and house work to be completed easily and efficiently without the sacrifice of power ...
(Date:8/30/2015)... ... August 31, 2015 , ... Although middle market companies ... issues that are critically important to them are often overlooked when government sets ... proposed legislation and changing tax and regulatory policies. Smaller companies, which often suffer ...
(Date:8/30/2015)... IL (PRWEB) , ... August 30, 2015 , ... ... is pleased to announce that Partner Daniel M. Kotin was recently elected ... this exclusive organization constitutes the highest degree of peer recognition and outstanding professionalism. ...
Breaking Medicine News(10 mins):Health News:National Ovarian Cancer Coalition Rolls Out "TAKE ACTION. NOT CHANCES. (SM)" Campaign for September, National Ovarian Cancer Awareness Month 2Health News:National Ovarian Cancer Coalition Rolls Out "TAKE ACTION. NOT CHANCES. (SM)" Campaign for September, National Ovarian Cancer Awareness Month 3Health News:One Stop Medical Center of Twin Cities Achieves Zero Failure Rate and Infection Rate in No Scalpel Vasectomy 2Health News:TheHardwareCity.com Now Offering Allied 49032 25 Piece Tri-Fold Tool Set 2Health News:Newport Board Group, an Advisory Firm Serving the Middle Market, Issues Five Tips on Selling Services to the Government 2Health News:Newport Board Group, an Advisory Firm Serving the Middle Market, Issues Five Tips on Selling Services to the Government 3Health News:Newport Board Group, an Advisory Firm Serving the Middle Market, Issues Five Tips on Selling Services to the Government 4Health News:Chicago Personal Injury Lawyer Daniel M. Kotin Elected to the American Board of Trial Advocates 2Health News:Chicago Personal Injury Lawyer Daniel M. Kotin Elected to the American Board of Trial Advocates 3
... in the treatment of intestinal disorders for close to ... to be extended to people with rectal cancer. In ... or "hand-assisted" laparoscopic surgery for rectal cancer, a team ... Medical Center has shown that the minimally invasive approach ...
... Nov. 10 Reportlinker.com announces that a ... its catalogue. , Central Nervous ... , http://www.reportlinker.com/p0161866/Central-Nervous-System-Insomnia-or-Sleep-Disorders.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire , ... or Sleep Disorders contains detailed information on ...
... at Kickoff Event , HARRISBURG, Pa., Nov. 10 ... in Pennsylvania by urging students to build a rewarding ... , "There will be rising demand for many ... seven years," said Governor Rendell. "During Health Careers Week, ...
... Texas Health Presbyterian Hospital Dallas is the first hospital in ... be named a Cycle III Chest Pain Center by the ... heart attack treatment. , "This honor means that Texas Health ... rapid recognition and collaborative treatment of heart attacks," said cardiologist ...
... Mayo Clinic research studied the association between prostate-specific antigen (PSA) ... of prostate growth is not necessarily a predictor for the ... a man,s PSA level is rising quickly, a prostate biopsy ... findings are being presented this week at the ...
... Medical School estimates 2,266 U.S. military veterans under the age of ... had reduced access to care. That figure is more than 14 ... Afghanistan in 2008, and more than twice as many as have ... 2001. The researchers, who released their analysis today, pointedly say ...
Cached Medicine News:Health News:Minimally invasive surgery shown safe and effective treatment for rectal cancer 2Health News:Minimally invasive surgery shown safe and effective treatment for rectal cancer 3Health News:Reportlinker Adds Central Nervous System Insomnia or Sleep Disorders 2Health News:Reportlinker Adds Central Nervous System Insomnia or Sleep Disorders 3Health News:PA Governor Rendell Puts Focus of Health Careers Week on In-Demand Occupations 2Health News:PA Governor Rendell Puts Focus of Health Careers Week on In-Demand Occupations 3Health News:Texas Health Dallas Receives Prestigious Chest Pain Accreditation 2Health News:Routine Evaluation of Prostate Size Not as Effective in Cancer Screening, Mayo Study Finds 2Health News:Routine Evaluation of Prostate Size Not as Effective in Cancer Screening, Mayo Study Finds 3Health News:Over 2,200 veterans died in 2008 due to lack of health insurance 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: